Erica Hong, Ph.D.

I work with clients to protect innovations in life sciences.

Her practice includes patent portfolio strategic planning, and preparation and prosecution of U.S., international, and foreign patent applications. She also assists clients with opinions regarding patent validity.

Erica has technical experience in genetics, cellular biology, biochemistry and biophysics. During her graduate work at Yale University, she studied the signaling pathway of DNA damage checkpoint. As a fellow of Leukemia and Lymphoma Society at Harvard Medical school, she studied the structure and dynamics of chromatin and heterochromatin.

As a research scientist at ImmunoGen, Inc., Erica developed technical expertise in oncology drug discovery. In particular, she gained expertise in antibodies and antibody-drug conjugates (ADC) as well as analytical methods for evaluating same. At ImmunoGen, Inc., Erica was involved with target validation, development of novel linkers/payloads, metabolite analysis, and alternate formats of antibody. In continuing her education, she studied controlled drug release at MIT, and initiation of clinical trials at Boston College.

Related Industries

Life Sciences

Related Practices

Patent Prosecution, Strategy & Management

Education

Boston University School of Law, J.D.
Yale University, Ph.D., Molecular, Cellular, Developmental Biology
University of Southern California (USC), B.S., Biological Sciences

Bar and Court Admissions

BAR ADMISSIONS

Massachusetts
U.S. Patent & Trademark Office (Agency)

Experience

Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, in its acquisition of StrideBio’s adeno-associated virus (AAV) capsid discovery and engineering platform assets

Other Publications

Reid EE, Archer KE, Shizuka M, Wilhelm A, Yoder NC, Bai C, Fishkin NE, Harris L, Maloney EK, Salomon P, Hong E, Wu R, Ab O, Jin S, Lai KC, Sikka S, Chari RVJ, Miller ML. (2019) Effect of Linker Stereochemistry on the Activity of Indolinobenzodiazepine Containing Antibody-Drug Conjugates (ADCs). ACS Med Chem Lett 10(8):1193-1197
Abrams, T., Connor, A., Fanton, C., Cohen, S., Huber, T., Miller, K., Hong, E., Niu, X., Kline, J., Ison-Dugenny, M., Harris, S., Walker, D., Krauser, K., Galimi, F., Wang, Z., Ghoddusi, M., Mansfield, K., Lee-Hoeflich, S., Holash, J., Pryer, N., Kluwe, W., Ettenberg, S., Sellers, W., Lees, E., Kwon, P., Abraham, J., Schleyer, S. (2018) Preclinical Antitumor Activity of a Novel Anti-c-KIT Antibody-Drug Conjugate against Mutant and Wild-type c-KIT-Positive Solid Tumors. Clin Cancer Res 24(17):4297-4308
Sun, X., Ponte, JF., Yoder, NC., Laleau, R., Coccia, J., Lanieri, L., Qiu, Q., Wu, R., Hong, E., Bogalhas, M., Wang, L., Dong, L., Setiady, Y., Maloney, EK., Ab, O., Zhang, X., Pinkas, J., Keating, TA., Chari, R., Erickson, HK., Lambert, JM. (2017) Effects of drug-antibody ratio on pharmacokinetics, biodistribution, efficacy, and tolerability of antibody-maytansinoid conjugates. Bioconjug Chem. 28(5):1371-1381
Singh, R., Setiady, Y., Ponte, J., Kovtun, Y., Lai, K., Hong, E., Fishkin, N., Dong, L., Jones, G., Coccia, J., Lanieri, L., Veale, K., Costoplus, J., Skaletskaya, A., Gabriel, R., Salomon, P., Wu, R., Qiu, Q., Erickson, H., Lambert, J., Chari, R., Widdison, W. (2016) A new, triglycyl peptide linker for antibody-drug conjugates (ADCs) with improved targeted killing of cancer cells. Molecular Cancer Therapeutics 15(6):1311-20
Widdison, W., Ponte, J., Coccia, J., Qiu, Q., Lanieri, L., Setiady, Y., Dong, L., Skaletskaya, A., Hong, E., Wu, R., Fishkin, N., Kovtun, Y., Veale, K., Wilhelm, S., Audette, C., Costoplus, J., Chari, R. (2015) Development of anilino-maytansinoid ADCs that induce high levels of bystander killing. Bioconjugate Chemistry 18;26(11):2261-78
Hong, E., Erickson, H., Lutz, R., Whiteman, K., Jones, G., Kovtun, Y., Blanc, V., Lambert, J. (2015) Design of Coltuximab Ravtansine, a CD19-targeting antibody-drug conjugate (ADC) for the treatment of B-cell malignancies: structure-activity relationships and preclinical evaluation. Mol Pharm. 12(6):1703-16
Hong, E., Chari, R. (2015) Linker design for antibody-drug conjugates, Antibody-drug conjugates, the 21st century magic bullets for cancer. AAPS Advances in the Pharmaceutical Sciences Series 17:49